Ketanserin NEW
| Price | $30 | $48 | $88 |
| Package | 25mg | 100mg | 200mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Ketanserin | CAS No.: 74050-98-9 |
| Purity: 99.19% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Ketanserin |
| Description | Ketanserin (Ketanserinum) is a quinazoline derivative and serotonin (5-hydroxytryptamine, 5HT) receptor subtype 2 (5-HTR2) antagonist with potential antihypertensive and antiplatelet activities. Following administration, ketanserin binds to and inhibits the signaling mediated by 5-HTR2, which inhibits serotonin-dependent vasoconstriction and platelet activation. |
| Cell Research | Ketanserin is dissolved in DMSO to produce a stock solution of 100 mM. Ketanserin stock is diluted in experimental solutions to achieve the final concentrations[1]. The established HEK 293 cell line stably expressing hERG channels is cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum, 400 μg/mL G418. The HEK 293 cell line stably expressing recombinant human cardiac KCNQ1/KCNE1 channel current (IKs) is maintained in DMEM containing 10% foetal bovine serum and 100 μg/mL hygromycin. Cells used for electrophysiology are seeded on a glass coverslip. The mutant hERG channels are constructed, and are transiently expressed in HEK 293 cells using 10 μL of Lipofectamine 2000 with 4 μg of hERG mutant cDNA in pCDNA3 vector[1]. |
| In vitro | In the acetic acid-induced writhing and hot plate tests, ketanserin exhibited dose-dependent analgesic effects in rats, with ED50 values of 0.62 mg/kg and 1.51 mg/kg, respectively; however, it showed no effect on the tail flick test. |
| In vivo | Research has demonstrated that Ketanserin reduces both the α1-adrenergic receptor-mediated responses and the excitation caused by norepinephrine in the lateral geniculate nucleus. This effect is indicative of induced inhibition rather than attenuation of 5-HT-mediated responses. In isolated rat tail and carotid arteries, dog basilar, gastric splenic and coronary arteries, as well as canine hidden veins and gastric splenic veins, Ketanserin dose-dependently inhibits the contraction induced by 5-hydroxytryptamine (5-HT). In rat cardiac myocytes, Ketanserin significantly prolongs the action potential duration, with repolarization reaching 218% at 50% and 256% at 90%, without significantly affecting other action potential parameters. Ketanserin inhibits the contraction of canine hidden veins and rat tail arteries induced by the activation of postsynaptic α-adrenergic receptors. In addition, Ketanserin inhibits the contractile response to 5-HT in perfused guinea pig gastric vessels and can reverse the response in some experiments. Ketanserin inhibits the transient outward potassium current (Ito) in a time- and concentration-dependent manner (EC50: 8.3 μM) and also dose-dependently inhibits both Ito and sustained currents (EC50: 11.2 μM), but does not affect L-type calcium currents or inward rectifier potassium currents. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 1.85 mg/mL (4.68 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 18.52 mg/mL (46.84 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.85 mg/mL (4.68 mM), Suspension. |
| Keywords | R-41468 | R 41468 | PotassiumChannel | Potassium Channel | Ketanserin | Autophagy | 5HTReceptor | 5-HT2C (Rat) | 5-HT2C (Human) | 5-HT2A | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $10.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-02 | |
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-07-02 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-02 | ||
|
VIP2Y
|
Wuhan Fortuna Chemical Co.,Ltd
|
2026-07-01 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $30.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2025-06-27 | |||
| $50.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY